{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:11:41Z","timestamp":1791425501622,"version":"4.3.3"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["5 P50 AR44855"],"award-info":[{"award-number":["5 P50 AR44855"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["K24 DK02759"],"award-info":[{"award-number":["K24 DK02759"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["1 UL1 RR025758-03"],"award-info":[{"award-number":["1 UL1 RR025758-03"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["RR-1066"],"award-info":[{"award-number":["RR-1066"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bone"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.bone.2010.11.012","type":"journal-article","created":{"date-parts":[[2010,11,25]],"date-time":"2010-11-25T04:48:02Z","timestamp":1290660482000},"page":"713-719","source":"Crossref","is-referenced-by-count":25,"title":["Time-dependent changes in skeletal response to teriparatide: Escalating vs. constant dose teriparatide (PTH 1\u201334) in osteoporotic women"],"prefix":"10.1016","volume":"48","author":[{"given":"Elaine W.","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Neer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason J.","family":"Wyland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda V.","family":"de la Paz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa C.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel S.","family":"Finkelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2010.11.012_bb0005","unstructured":"Finkelstein JS. Osteoporosis. 21st edition ed. ed. Philadelphia: W.B. Saunders Company; 2000."},{"key":"10.1016\/j.bone.2010.11.012_bb0010","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2010.11.012_bb0015","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2010.11.012_bb0020","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2010.11.012_bb0025","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJM199412153312404","article-title":"Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency","volume":"331","author":"Finkelstein","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2010.11.012_bb0030","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1210\/jc.2002-020334","article-title":"A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1\u201334)] with alendronate in postmenopausal women with osteoporosis","volume":"87","author":"Body","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2010.11.012_bb0035","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","article-title":"Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis","volume":"350","author":"Lindsay","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2010.11.012_bb0040","first-page":"3069","article-title":"Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers","volume":"85","author":"Kurland","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2010.11.012_bb0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1\u201334)] therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.012_bb0050","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2010.11.012_bb0055","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1210\/jc.2006-0190","article-title":"Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men","volume":"91","author":"Finkelstein","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2010.11.012_bb0060","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.bone.2010.11.012_bb0065","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1210\/jc.2008-2719","article-title":"Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent","volume":"94","author":"Cosman","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2010.11.012_bb0070","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jama.280.12.1067","article-title":"Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1\u201334): a randomized controlled trial","volume":"280","author":"Finkelstein","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2010.11.012_bb0075","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1359\/JBMR.050105","article-title":"Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis","volume":"20","author":"Chen","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.012_bb0080","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa050157","article-title":"Daily and cyclic parathyroid hormone in women receiving alendronate","volume":"353","author":"Cosman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2010.11.012_bb0085","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate","volume":"19","author":"Ettinger","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.012_bb0090","first-page":"620","article-title":"A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis","volume":"82","author":"Hodsman","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2010.11.012_bb0095","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s001980070111","article-title":"Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis","volume":"11","author":"Lane","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2010.11.012_bb0100","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1210\/jc.2003-030768","article-title":"Efficacy and safety of human parathyroid hormone-(1\u201384) in increasing bone mineral density in postmenopausal osteoporosis","volume":"88","author":"Hodsman","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2010.11.012_bb0105","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","article-title":"Effect of recombinant human parathyroid hormone (1\u201384) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bone.2010.11.012_bb0110","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1210\/jc.2007-2781","article-title":"Randomized trial of once-weekly parathyroid hormone (1\u201384) on bone mineral density and remodeling","volume":"93","author":"Black","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2010.11.012_bb0115","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/jbmr.5650110403","article-title":"Sequential effects of chronic human PTH (1\u201384) treatment of estrogen-deficiency osteopenia in the rat","volume":"11","author":"Mitlak","year":"1996","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.012_bb0120","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1210\/jc.2005-1712","article-title":"Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis","volume":"91","author":"Bauer","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2010.11.012_bb0125","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1210\/jc.2009-0154","article-title":"Effects of teriparatide retreatment in osteoporotic men and women","volume":"94","author":"Finkelstein","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2010.11.012_bb0130","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2010.11.012_bb0135","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1359\/jbmr.080506","article-title":"Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment","volume":"23","author":"Obermayer-Pietsch","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.012_bb0140","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2010.11.012_bb0145","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1210\/jc.2009-1703","article-title":"Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis","volume":"95","author":"Finkelstein","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2010.11.012_bb0150","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1359\/jbmr.1997.12.4.652","article-title":"Total body bone mineral density in young children: influence of head bone mineral density","volume":"12","author":"Taylor","year":"1997","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.11.012_bb0155","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/00004424-198505000-00014","article-title":"Quantitative computed tomography for spinal density measurement. Factors affecting precision","volume":"20","author":"Rosenthal","year":"1985","journal-title":"Investig Radiol"},{"key":"10.1016\/j.bone.2010.11.012_bb0160","doi-asserted-by":"crossref","first-page":"16525","DOI":"10.1073\/pnas.0808750105","article-title":"Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation","volume":"105","author":"Okazaki","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bone.2010.11.012_bb0165","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2010.11.012_bb0170","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.abb.2008.03.003","article-title":"Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone","volume":"473","author":"Goltzman","year":"2008","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.bone.2010.11.012_bb0175","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.bone.2007.03.017","article-title":"Molecular and cellular mechanisms of the anabolic effect of intermittent PTH","volume":"40","author":"Jilka","year":"2007","journal-title":"Bone"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328210020430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328210020430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T10:49:20Z","timestamp":1559818160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328210020430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S8756328210020430"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2010.11.012","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}